Read by QxMD icon Read

idiopathic inflammatory myopathy

Konstantinos Parperis
I read with great interest the article by Antovic et al, recently published in Arthritis Care & Research (1). In a population-based study, the investigators demonstrated an increased risk of venous thromboembolic events (VTE) in patients with idiopathic inflammatory myopathy (IIM), compared with the general population. Strikingly, the hazard ratio for VTE was 26.6 (95% CI 10.4, 68.0) the first year of diagnosis. The authors reported that 34.8% of patients with IIM versus 0.9% in the control group were taking glucocorticoids, however further data analysis might have been contacted in order to evaluate for possible association of glucocorticoid exposure and increased risk of VTE...
February 14, 2019: Arthritis Care & Research
Fabricio Espinosa-Ortega, Marie Holmqvist, Helene Alexanderson, Helena Storfors, Tsuneyo Mimori, Ingrid E Lundberg, Johan Rönnelid
No abstract text is available yet for this article.
February 13, 2019: Annals of the Rheumatic Diseases
N Ferdowsi, W Stevens, M Baron, M Nikpour
OBJECTIVE: To review the current literature, and evaluate the psychometric properties of disease damage indices in rheumatic diseases. METHODS: A search of Medline, EMBASE, and Cochrane Library databases was performed to June 2018 to identify damage indices in all systemic rheumatic diseases. Articles were included in a systematic review if indices were composite (multi-organ) in nature and if adequate detail on methodology was described. Articles pertaining to the validation of these indices were also reviewed in order to assess the psychometric properties of the indices using the Outcome Measures in Rheumatology Arthritis Clinical Trials (OMERACT) filter as a guide...
January 17, 2019: Seminars in Arthritis and Rheumatism
Sundaram Challa, Monalisa Hui, Saumya Jakati, Megha Shantveer Uppin, Liza Rajasekhar, Meena Angamuthu Kannan, Lokesh Lingappa, Murthy Murali Krishna Jagarlapudi
Background: Juvenile idiopathic inflammatory myopathies (JIIM) are rare and heterogeneous. Subtype identification is important for treatment. Materials and Methods: Patients below 18 years diagnosed as idiopathic inflammatory myopathy (IIM) according to the Bohan and Peter criteria between January 2010 and May 2015 were evaluated with muscle biopsy in the four domains: muscle fiber, inflammation, connective tissue, and vascular, with basic panel of histochemical stains as per recommendations of the European Neuromuscular center (ENMC) workshop 2015...
January 2019: Indian Journal of Pathology & Microbiology
Naohiro Uchio, Kenichiro Taira, Chiseko Ikenaga, Masato Kadoya, Atsushi Unuma, Kenji Yoshida, Setsu Nakatani-Enomoto, Yuki Hatanaka, Yasuhisa Sakurai, Yasushi Shiio, Kenichi Kaida, Akatsuki Kubota, Tatsushi Toda, Jun Shimizu
Objective: To provide evidence that idiopathic inflammatory myopathy (IM) with myasthenia gravis (MG) frequently shows thymoma association and polymyositis (PM) pathology and shares clinicopathologic characteristics with IM induced by immune checkpoint inhibitors (ICIs). Methods: We analyzed the clinicopathologic features of 10 patients with idiopathic IM and MG identified in 970 consecutive patients with biopsy-proven IM. Results: Seven patients (70%) had thymoma...
March 2019: Neurology® Neuroimmunology & Neuroinflammation
Valérie Leclair, Angeles Shunashy Galindo-Feria, Maryam Dastmalchi, Marie Holmqvist, Ingrid E Lundberg
Objective: Post-hoc analyses of the Rituximab in Myositis trial indicate that specific autoantibodies profiles may influence treatment response. We compared the efficacy and safety of rituximab in anti-synthetase antibody (ARS-ab) positive and negative patients. Methods: Adult idiopathic inflammatory myopathy (IIM) subjects in the Swedish Rheumatology Quality Register who received ⩾ 1 cycle of rituximab were enrolled. Efficacy assessment was based on the International Myositis Assessment and Clinical Studies (IMACS) core set measures and the 2016 ACR/EULAR definition of improvement for PM and DM...
January 25, 2019: Rheumatology
A D Tudorancea, P L Ciurea, F A Vreju, E M Vintila, Ș C Dinescu
Dermatomyositis (DM) is part of a heterogeneous group of systemic diseases called idiopathic inflammatory myopathies. As in other autoimmune connective tissue diseases (CTD), abnormalities of hematopoietic tissue and/or peripheral blood cells may develop and represent an important prognostic factor. Most common CTD associated with thrombocytopenia (TP) are systemic lupus erythematosus and antiphospholipid syndrome. DM-related TP is less frequent and may develop in the context of an underlying malignancy. Severe TP related to myositis is a very rare occurrence...
April 2018: Current Health Sciences Journal
Lucie Andrés Cerezo, Hana Hulejová, Barbora Šumová, Tereza Kropáčková, Olga Kryštůfková, Martin Klein, Heřman F Mann, Josef Zámečník, Ondřej Pecha, Karel Pavelka, Jiří Vencovský, Ladislav Šenolt
BACKGROUND: S100A11 (calgizzarin), a member of the S100 family, is associated with oncogenesis, inflammation and myocardial damage. Our aim was to analyse S100A11 in idiopathic inflammatory myopathies (IIMs) and its association with disease activity features and cancer development. METHODS: S100A11 in muscle was determined by immunohistochemistry in polymyositis (PM), dermatomyositis (DM), myasthenia gravis (MG) and in subjects without autoimmune inflammatory disease (HC)...
January 23, 2019: Cytokine
Shereen Paramalingam, Peter Counsel, Frank L Mastaglia, Helen Keen, Merrilee Needham
Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of muscle diseases that carry a significant morbidity and mortality risk. The utilization of imaging in the diagnostic pathway of IIM is therefore important to obtain early diagnosis and even monitor patients over time. Areas covered: Magnetic resonance imaging (MRI) has been the main imaging modality used to detect myositis but limitations include cost and accessibility, leading to delays in time to scan, and patient contraindications. This has led to the exploration of other imaging techniques to diagnose and monitor response to therapy...
February 2019: Expert Review of Neurotherapeutics
Fernando Henrique Carlos de Souza, Renata Miossi, Júlio Cesar Bertacini de Moraes, Eloisa Bonfá, Samuel Katsuyuki Shinjo
BACKGROUND: Interpretation of rituximab efficacy for refractory idiopathic inflammatory myopathies (IIM) is hampered by the absence of a uniform definition of refractory myositis and clinical response. Therefore, rigorous criteria of refractoriness, together with a homogenous definition of clinical improvement, were used to evaluate rituximab one-year response. METHODS: A retrospective cohort study including 43 IIM (15 antisynthetase syndrome, 16 dermatomyositis, 12 polymyositis) was conducted...
September 18, 2018: Advances in rheumatology
Céline Anquetil, Olivier Boyer, Nadège Wesner, Olivier Benveniste, Yves Allenbach
Over the past few years, myositis-specific autoantibodies played an increasing role in the inflammatory idiopathic myositis definition. They became the critical immunological marker for immune-mediated necrotizing myopathy diagnosis (IMNM) since the paradigm switch from histological to serological criteria. This review is focused on the key role of the anti-signal recognition particle (anti-SRP) and the anti-3-Hydroxy-3-MethylGlutaryl-Coenzyme A Reductase (anti-HMGCR) antibodies in immune-mediated necrotizing myopathy...
January 10, 2019: Autoimmunity Reviews
Jan Damoiseaux, Jean-Baptiste Vulsteke, Chih-Wei Tseng, Anouk C M Platteel, Yves Piette, Ora Shovman, Carolien Bonroy, Dörte Hamann, Ellen De Langhe, Lucille Musset, Yi-Hsing Chen, Yehuda Shoenfeld, Yves Allenbach, Xavier Bossuyt
Idiopathic inflammatory myopathies (IIM) are a group of diseases characterized by immune-mediated muscular lesions that may be associated with extra-muscular manifestations involving skin, lungs, heart or joints. Four main groups of IIM can be distinguished: dermatomyositis (DM), overlap myositis including mainly anti-synthetase syndrome (ASS), immune mediated necrotizing myopathy (IMNM), and inclusion body myositis (IBM). Myositis-specific autoantibodies (MSA) are increasingly recognized as valuable tools for diagnosis, classification and prognosis of IIM...
January 10, 2019: Autoimmunity Reviews
Karim Asi, Anand Gourishankar, Ankur Kamdar
BACKGROUND: Idiopathic inflammatory myopathies (IIM) are a group of systemic autoimmune disorders primarily affecting skeletal muscle. Pediatric coronary artery dilation is frequently discussed in Kawasaki disease. However, it has yet to be reported in the IIMs or antisynthetase syndrome. We report a unique case of a patient with IIM, antisynthetase syndrome and coronary artery dilation. CASE PRESENTATION: We report an adolescent presenting with joint symptoms, fever, and eye swelling with a clinical diagnosis of Juvenile Dermatomyositis...
January 10, 2019: Pediatric Rheumatology Online Journal
Adam M Huber
No abstract text is available yet for this article.
January 2019: Journal of Rheumatology
Kaiwen Wang, Jiangfeng Zhao, Zhiwei Chen, Ting Li, Xiaoming Tan, Yu Zheng, Liyang Gu, Li Guo, Fangfang Sun, Haiting Wang, Jiajie Li, Xiaodong Wang, Gabriela Riemekasten, Shuang Ye
No abstract text is available yet for this article.
December 22, 2018: Rheumatology
Divya Jayakumar, Rui Zhang, Amy Wasserman, Julia Ash
Idiopathic inflammatory myopathies are a group of autoimmune diseases that are characterized by muscle inflammation resulting in elevated muscle enzyme release and distinctive biopsy findings. This group of conditions includes polymyositis, dermatomyositis, inclusion body myositis and necrotizing autoimmune myopathy. Although they have many similarities, the inflammatory myopathies differ in their clinical, pathological and treatment realms. Extra-muscular manifestations may involve many organs that include the skin, joints, heart, lungs and gastrointestinal tract...
December 21, 2018: Cardiology in Review
Elisabet Zamora, Elena Seder-Colomina, Susana Holgado, Bibiana Quirant-Sanchez, José Luis Mate, Eva M Martínez-Cáceres, Ivette Casafont, Antoni Bayés-Genís
A 78-year-old man with 3 months of progressive dyspnea, dysphony, dysgeusia, and proximal muscle weakness was diagnosed of probably idiopathic inflammatory myopathy with nonspecific interstitial pneumonia. Variable degrees of atrioventricular block and persistently elevated cardiac enzymes indicated a diagnosis of myocarditis, confirmed with cardiac magnetic resonance imaging and endomyocardial biopsy. A comprehensive immune work-up revealed anti-small ubiquitin-like modifier-1 activating enzyme (anti-SAE) antibody, a novel myositis-specific antibody, previously described mainly with overt cutaneous dermatomyositis and late skeletal muscle manifestations...
December 23, 2018: Journal of Clinical Medicine
Ying Hou, Meirong Liu, Yue-Bei Luo, Yuan Sun, Kai Shao, Tingjun Dai, Wei Li, Yuying Zhao, Chuanzhu Yan
Anti-mitochondrial antibodies, the hallmark of primary biliary cirrhosis, have been detected in many patients with idiopathic inflammatory myopathies and these anti-mitochondrial-antibody-associated idiopathic inflammatory myopathies frequently show unique characteristics. We detected anti-mitochondrial antibodies in Chinese idiopathic inflammatory myopathy and summarized the clinical findings of these anti-mitochondrial-antibody-positive patients. Of 136 patients, seven (5.15%) were found to be anti-mitochondrial-antibody-positive...
November 22, 2018: Neuromuscular Disorders: NMD
Vincent Casteleyn, Helena Radbruch, Torsten Diekhoff, Thomas Rose, Lydia Spengler, Udo Schneider, Werner Stenzel
Immunoglobulin (Ig)G4-related disease is an uncommon systemic autoimmune disorder characterized by infiltration of IgG4+ plasma cells in different organs and elevated levels of IgG4 in peripheral blood. So far, only one case of myositis with abundant IgG4+ plasma cells has been reported and classified as 'polymyositis'. We present an unusual case of chronic inflammatory myopathy in a context of rheumatoid arthritis. Severe granulomatous myositis, featuring abundant IgG4+ plasma cells was identified in two skeletal muscle biopsies within a five-year-interval...
November 24, 2018: Neuromuscular Disorders: NMD
Marialbert Acosta-Herrera, Martin Kerick, David González-Serna, Cisca Wijmenga, Andre Franke, Peter K Gregersen, Leonid Padyukov, Jane Worthington, Timothy James Vyse, Marta Eugenia Alarcón-Riquelme, Maureen D Mayes, Javier Martin
OBJECTIVE: Immune-mediated inflammatory diseases (IMIDs) are heterogeneous and complex conditions with overlapping clinical symptoms and elevated familial aggregation, which suggests the existence of a shared genetic component. In order to identify this genetic background in a systematic fashion, we performed the first cross-disease genome-wide meta-analysis in systemic seropositive rheumatic diseases, namely, systemic sclerosis, systemic lupus erythematosus, rheumatoid arthritis and idiopathic inflammatory myopathies...
December 20, 2018: Annals of the Rheumatic Diseases
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"